Scott Newman

Scott Newman

Auto-generated profile, based on publicly available information

Scott Newman

Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Molecular Cell
Verified
Journal Article
Closed access
TCTamir Chandra
Tamir Chandra
KKKristina Kirschner
Kristina Kirschner
JTJean-Yves Thuret
Jean-Yves Thuret
BPBenjamin D. Pope
Benjamin D. Pope
TRTyrone Ryba
Tyrone Ryba
MNMasashi Narita
Masashi Narita

14 March 2019 in Genome Biology
Verified
Journal Article
Open access
PDF file
XMXiaotu Ma
Xiaotu Ma
YSYing Shao
Ying Shao
LTLiqing Tian
Liqing Tian
DFDiane A. Flasch
Diane A. Flasch
HMHeather L. Mulder
Heather L. Mulder
JZJinghui Zhang
Jinghui Zhang
Sequencing errors are key confounding factors for detecting low-frequency genetic variants that are important for cancer molecular diagnosis, treatment, and surveillance using deep next-generation sequencing (NGS). However, there is a lack of comprehensive understanding of errors introduced at various steps of a conventional NGS workflow, such as sample handling, library preparation, PCR enrichment, and sequencing. In this study, we use current NGS technology to systematically investigate these questions. By evaluating read-specific error distributions, we discover that the substitution error rate can be computationally suppressed to 10−5 to 10−4, which is 10- to 100-fold lower than generally considered achievable (10−3) in the current literature. We then quantify substitution errors attributable to sample handling, library preparation, enrichment PCR, and sequencing by using multiple deep sequencing datasets. We find that error rates differ by nucleotide substitution types, ranging from 10−5 for A>C/T>G, C>A/G>T, and C>G/G>C changes to 10−4 for A>G/T>C changes. Furthermore, C>T/G>A errors exhibit strong sequence context dependency, sample-specific effects dominate elevated C>A/G>T errors, and target-enrichment PCR led to ~ 6-fold increase of overall error rate. We also find that more than 70% of hotspot variants can be detected at 0.1 ~ 0.01% frequency with the current NGS technology by applying in silico error suppression. We present the first comprehensive analysis of sequencing error sources in conventional NGS workflows. The error profiles revealed by our study highlight new directions for further improving NGS analysis accuracy both experimentally and computationally, ultimately enhancing the precision of deep sequencing.

29 March 2011 in Science Signaling
Verified
Journal Article
Closed access
PDF file
ALAnnette S. Little
Annette S. Little
KBKathryn Balmanno
Kathryn Balmanno
MSMatthew J. Sale
Matthew J. Sale
SNScott Newman
Scott Newman
JDJonathan R. Dry
Jonathan R. Dry
SCSimon J. Cook
Simon J. Cook
The acquisition of resistance to protein kinase inhibitors is a growing problem in cancer treatment. We modeled acquired resistance to the MEK1/2 (mitogen-activated or extracellular signal–regulated protein kinase kinases 1 and 2) inhibitor selumetinib (AZD6244) in colorectal cancer cell lines harboring mutations in BRAF (COLO205 and HT29 lines) or KRAS (HCT116 and LoVo lines). AZD6244-resistant derivatives were refractory to AZD6244-induced cell cycle arrest and death and exhibited a marked increase in ERK1/2 (extracellular signal–regulated kinases 1 and 2) pathway signaling and cyclin D1 abundance when assessed in the absence of inhibitor. Genomic sequencing revealed no acquired mutations in MEK1 or MEK2, the primary target of AZD6244. Rather, resistant lines showed a marked up-regulation of their respective driving oncogenes, BRAF600E or KRAS13D, due to intrachromosomal amplification. Inhibition of BRAF reversed resistance to AZD6244 in COLO205 cells, which suggested that combined inhibition of MEK1/2 and BRAF may reduce the likelihood of acquired resistance in tumors with BRAF600E. Knockdown of KRAS reversed AZD6244 resistance in HCT116 cells as well as reduced the activation of ERK1/2 and protein kinase B; however, the combined inhibition of ERK1/2 and phosphatidylinositol 3-kinase signaling had little effect on AZD6244 resistance, suggesting that additional KRAS effector pathways contribute to this process. Microarray analysis identified increased expression of an 18-gene signature previously identified as reflecting MEK1/2 pathway output in resistant cells. Thus, amplification of the driving oncogene (BRAF600E or KRAS13D) can drive acquired resistance to MEK1/2 inhibitors by increasing signaling through the ERK1/2 pathway. However, up-regulation of KRAS13D leads to activation of multiple KRAS effector pathways, underlining the therapeutic challenge posed by KRAS mutations. These results may have implications for the use of combination therapies.

12 October 2011 in Genome Research
Verified
Journal Article
Open access
PDF file
CGChris D. Greenman
Chris D. Greenman
EPErin D. Pleasance
Erin D. Pleasance
SNScott Newman
Scott Newman
FYFengtang Yang
Fengtang Yang
BFBeiyuan Fu
Beiyuan Fu
PCPeter J. Campbell
Peter J. Campbell
Cancer genomes are complex, carrying thousands of somatic mutations including base substitutions, insertions and deletions, rearrangements, and copy number changes that have been acquired over decades. Recently, technologies have been introduced that allow generation of high-resolution, comprehensive catalogs of somatic alterations in cancer genomes. However, analyses of these data sets generally do not indicate the order in which mutations have occurred, or the resulting karyotype. Here, we introduce a mathematical framework that begins to address this problem. By using samples with accurate data sets, we can reconstruct relatively complex temporal sequences of rearrangements and provide an assembly of genomic segments into digital karyotypes. For cancer genes mutated in rearranged regions, this information can provide a chronological examination of the selective events that have taken place.

4 March 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SNScott Newman
Scott Newman
LFLiying Fan
Liying Fan
APAllison Pribnow
Allison Pribnow
ASAntonina Silkov
Antonina Silkov
SRStephen V. Rice
Stephen V. Rice
Armita BahramiArmita Bahrami
Armita Bahrami

19 December 2011 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
CNCharlotte K Y Ng
Charlotte K Y Ng
SCSusanna L Cooke
Susanna L Cooke
KHKevin Howe
Kevin Howe
SNScott Newman
Scott Newman
JXJian Xian
Jian Xian
JBJames D Brenton
James D Brenton